Cancer News and Research

Latest Cancer News and Research

Viral Genetics: Company update

Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer to clinical trials.

12 Feb 2010

Histone modifications associated with pancreatic cancer development and progression

Specific chemical modifications to proteins called histones, which are found in the nucleus of cells and act as spools around which DNA is wound, can be used to predict prognosis and response to treatment in subsets patients with pancreatic cancer, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

12 Feb 2010

Gold nanoparticles for cancer treatment

World Gold Council (WGC) has today published 'Gold for Good: Gold and nanotechnology in the age of innovation', a research paper detailing new scientific and technological innovations using gold. The report, which was produced in conjunction with Cientifica Ltd, the world's leading source of global business and investor intelligence about nanotechnologies, demonstrates how gold nanoparticles offer the potential to overcome many of the serious issues facing mankind over the coming decades.

12 Feb 2010

New project to unravel secret lives of cancer cells may help produce new cancer therapies

A team of scientists from Princeton University and The Cancer Institute of New Jersey has embarked on a major new project to unravel the secret lives of cancer cells that go dormant and self-cannibalize to survive periods of stress. The work may help produce new cancer therapies to stem changes that render cancer cells dangerous and resistant to treatment.

12 Feb 2010

PAN to provide co-payment assistance for medications to underinsured patients through five new funds

Patient Access Network Foundation will expand its services to provide co-payment assistance for medications to underinsured patients through five new funds -- including grants of up to $10,000 per year for prostate cancer patients.

12 Feb 2010

Cal-EPA intents to add BPA to state's list of chemicals known to cause cancer

The California Environmental Protection Agency signaled intent to add bisphenol A (BPA) to the state's list of chemicals known to cause cancer or birth defects, adding to evidence the chemical should be banned from food and beverage containers.

12 Feb 2010

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.

12 Feb 2010

IPF added to Social Security's "Compassionate Allowances" program

The Coalition for Pulmonary Fibrosis is praising Social Security Commissioner Michael Astrue's announcement this morning via press release that Idiopathic Pulmonary Fibrosis (IPF), also known as Pulmonary Fibrosis (PF), and a listing of 37 other diseases and life-threatening medical conditions are the latest additions to Social Security's "Compassionate Allowances" program.

12 Feb 2010

MITA endorses eight key principles to reduce unnecessary radiation exposure and medical errors

The Medical Imaging & Technology Alliance (MITA), the leading association representing the manufacturers, innovators and developers of medical imaging and radiation therapy systems, today endorsed eight key principles to reduce exposure to unnecessary medical radiation, further minimize medical errors and improve reporting of adverse events.

12 Feb 2010

Study shows benefits of stent grafts over balloon angioplasty for patients who undergo dialysis

A randomized multicenter study of 190 patients at 13 medical centers shows-- for the first time-- the "superior" benefit of stent grafts over balloon angioplasty for maintaining function of dialysis access grafts in kidney failure patients who undergo dialysis. Until now, no other therapy has proven more effective than angioplasty.

12 Feb 2010

Third party reexamination of Phase III study of Ereska meets primary endpoint

Javelin Pharmaceuticals, Inc. today announced that a reexamination conducted by a third party of pain score measurements from its Phase III study of Ereska™ (intranasal ketamine) showed that top line results for its primary endpoint were statistically significant. Previously, Javelin had reported that the top line results for its primary endpoint were not statistically significant.

12 Feb 2010

United Airlines to deliver teddy bears to kids undergoing cancer treatment across the country

Starting today, United Airlines employees will begin delivering thousands of teddy bears to kids undergoing cancer treatment at hospitals across the country through a partnership with the American Cancer Society® that raised almost 27 million Mileage Plus miles.

12 Feb 2010

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

A leading immunology research institute has validated the long-held and controversial hypothesis that antibodies - usually the "good guys" in the body's fight against viruses - instead contribute to severe dengue virus-induced disease, the La Jolla Institute for Allergy & Immunology announced today. The finding has major implications for the development of a first-ever vaccine against dengue virus, a growing public health threat which annually infects 50 to 100 million people worldwide, causing a half million cases of the severest form.

12 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

IBM, VLSCI scientists to use Blue Gene supercomputer to study human disease

IBM today announced a Research collaboratory in Melbourne, Australia, where scientists from the Victorian Life Sciences Computational Initiative at the University of Melbourne and the IBM Research Computational Biology Center will use high performance computing – including IBM's Blue Gene supercomputer – to study human disease.

12 Feb 2010

CapitalBio officially joins Roche NimbleGen CSP Program

Roche NimbleGen announced today that Beijing-based genomic services provider CapitalBio has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program.

12 Feb 2010

NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services

Biologics, Inc., the leading cancer management company in the United States, announces that its Oncology Clinical Trial Services division has been selected by the National Marrow Donor Program® (NMDP), a nonprofit organization that facilitates unrelated hematopoietic cell transplants.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

Researchers identify potential drug candidate that halts tumor growth

A novel - and rapid - anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic tumors from growing in mice. Researchers at the Moores Cancer Center at the University of California, San Diego, have found a drug that binds to a molecular "switch" found in cancer cells and cancer-associated blood vessels to keep it in the "off" position.

12 Feb 2010

Cancer drug could be effective for treating recurrent nose bleeds

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin.

12 Feb 2010

Cancer News and Research

Latest Cancer News and Research

Viral Genetics: Company update

Histone modifications associated with pancreatic cancer development and progression

Gold nanoparticles for cancer treatment

New project to unravel secret lives of cancer cells may help produce new cancer therapies

PAN to provide co-payment assistance for medications to underinsured patients through five new funds

Cal-EPA intents to add BPA to state's list of chemicals known to cause cancer

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

IPF added to Social Security's "Compassionate Allowances" program

MITA endorses eight key principles to reduce unnecessary radiation exposure and medical errors

Study shows benefits of stent grafts over balloon angioplasty for patients who undergo dialysis

Third party reexamination of Phase III study of Ereska meets primary endpoint

United Airlines to deliver teddy bears to kids undergoing cancer treatment across the country

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

IBM, VLSCI scientists to use Blue Gene supercomputer to study human disease

CapitalBio officially joins Roche NimbleGen CSP Program

NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services

Second-quarter fiscal 2010 results announced by Pharmacyclics

Researchers identify potential drug candidate that halts tumor growth

Cancer drug could be effective for treating recurrent nose bleeds

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in